Argus analyst Jasper Hellweg raised his price target on Vertex to $194 and kept his Buy rating after the company's launch of phase 3 trial of the first of two triple-combination CF regimens this week. The analyst states that the earnings outlook for the company is also positive after a "strong quarter for core products Orkambi and Kalydeco, as well as the introduction of a new CF drug, Symdeko". Based on Vertex's growth outlook, Hellweg states that the premium valuation of 14.4-times projected FY18 sales - above 12.2-times peer average - is warranted.